Valiant Laboratories Ltd

Valiant Laboratories Ltd

₹ 161 -4.72%
12 Apr 3:40 p.m.
About

Incorporated in 1980, Valiant Laboratories Limited is a pharmaceutical ingredient manufacturing company in India having focuses on manufacturing Paracetamol.[1]

Key Points

Business Profile[1] The company manufactures a single product, i.e., Paracetamol, which has several applications, like in treatment headache, muscle ache, arthritis, back ache, toothache, cold, and fever. Paracetamol is one of the most commonly taken analgesics worldwide and is recommended as the first-line therapy in pain conditions by the World Health Organization (WHO).

  • Market Cap 700 Cr.
  • Current Price 161
  • High / Low 227 / 139
  • Stock P/E 24.2
  • Book Value 24.3
  • Dividend Yield 0.00 %
  • ROCE %
  • ROE %
  • Face Value 10.0

Pros

Cons

  • Stock is trading at 7.00 times its book value

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2022 Dec 2022 Jun 2023 Sep 2023 Dec 2023
87.96 70.77 51.41 59.55 40.52
77.28 60.84 47.59 60.94 46.83
Operating Profit 10.68 9.93 3.82 -1.39 -6.31
OPM % 12.14% 14.03% 7.43% -2.33% -15.57%
1.47 0.78 2.44 2.96 1.78
Interest 0.17 0.04 0.02 0.02 0.02
Depreciation 0.37 0.40 0.46 0.49 0.49
Profit before tax 11.61 10.27 5.78 1.06 -5.04
Tax % 25.50% 25.51% 26.12% 25.47% 30.75%
8.66 7.65 4.27 0.79 -3.50
EPS in Rs 5.32 4.70 1.31 0.24 -0.81
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023
334
299
Operating Profit 35
OPM % 11%
5
Interest 0
Depreciation 2
Profit before tax 38
Tax % 24%
29
EPS in Rs 8.91
Dividend Payout % 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: %
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: %
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: %

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Sep 2023
Equity Capital 33 33
Reserves 68 73
60 61
52 49
Total Liabilities 213 215
48 50
CWIP 1 11
Investments 34 20
130 135
Total Assets 213 215

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023
56
-55
-1
Net Cash Flow -0

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023
Debtor Days 97
Inventory Days 17
Days Payable 62
Cash Conversion Cycle 52
Working Capital Days 71
ROCE %

Shareholding Pattern

Numbers in percentages

2 Recently
Sep 2023Dec 2023Mar 2024
74.94% 74.94% 74.94%
8.64% 7.08% 3.48%
1.76% 0.43% 0.00%
14.66% 17.54% 21.58%
No. of Shareholders 37,43415,82114,914

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents